Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 11, 2015, Pages

  Smith, Lesley A ^a   Azariah, Fredric ^a   Lavender, Verna Tc ^a   Stoner, Nicola S ^b   Bettiol, Silvana ^c  

^a OXFORD BROOKES UNIVERSITY   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TASMANIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; PROCHLORPERAZINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CHLORPROMAZINE; DOMPERIDONE; METOCLOPRAMIDE;

ADVERSE EVENT; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; EUPHORIA; HALLUCINATION; HUMAN; MONOTHERAPY; NAUSEA AND VOMITING; ORTHOSTATIC HYPOTENSION; PARANOIA; PATIENT PREFERENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; ADULT; CHEMICALLY INDUCED; META ANALYSIS; NAUSEA; NEOPLASMS; VOMITING;

ADULT; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CANNABINOIDS; CHLORPROMAZINE; DIZZINESS; DOMPERIDONE; EUPHORIA; HUMANS; METOCLOPRAMIDE; NAUSEA; NEOPLASMS; PROCHLORPERAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VOMITING;

EID: 84955108820     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009464.pub2     Document Type: Review

References (175)

1. Ahmedzai S, Carlyle DL, Calder IT, Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. British Journal of Cancer 1983;48(5):657-63.
2. Chang AE, Shiling DJ, Stillman RC. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Annals of Internal Medicine 1979;91(6):819-24.
3. Chang AE, Shiling DJ, Stillman RC. A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 1981;47(7):1746-51.
4. Crawford SM, Buckman R. Nabilone and metoclopramide in the treatment of nausea and vomiting due to cisplatinum: a double blind study. Medical Oncology and Tumor Pharmacotherapy 1986;3(1):39-42.
5. Einhorn LH, Nagy C, Furnas B, Williams SD. Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. Journal of Clinical Pharmacology 1981;21(8-9 Suppl):64S-9S.
6. Frytak S, Moertel CG, O'Fallon JR. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Annals of Internal Medicine 1979;91(6):825-30.
7. George M, Pejovic MH, Thuaire M, Kramar A, Wolff JP. Randomized comparative trial of a new anti-emetic: nabilone, in cancer patients treated with cisplatin [French]. Biomedicine & Pharmacotherapy 1983;37(1):24-7.
8. Gralla RJ Tyson LB Bordin LA. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treatment Reports 1984;68(1):163-72.
9. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New England Journal of Medicine 1979; Vol. 300:1295-7.
10. Johansson R, Kilkku P, Groenroos M. A double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy. Cancer Treatment Reviews 1982;9(Suppl B):25-33.
11. Jones SE, Durant JR, Greco FA, Robertone A. A multi-institutional phase III study of nabilone vs. placebo in chemotherapy-induced nausea and vomiting. Cancer Treatment Reviews 1982;9(Suppl B):45-8.
12. Kleinman S, Weitzman SA, Cassem N, Andrews E. Double blind trial of delta-9-tetrahydrocannabinol (THC) versus placebo as an adjunct to prochlorperazine for chemotherapy-induced vomiting. Current Therapeutic Research - Clinical and Experimental 1983;33(61):1014-7.
13. Kluin-Neleman JC, Neleman FA, Meuwissen OJ, Maes RA. Delta 9-tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancer chemotherapy; a double-blind cross-over trial against placebo. Veterinary & Human Toxicology 1979;21(5):338-40.
14. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JL, Hamm J, et al. Dronabinol and prochlorperazine in combination for treatment of cancer chemotherapy-induced nausea and vomiting. Journal of Pain and Symptom Management 1991;6(6):352-9.
15. Levitt M. Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients. Cancer Treatment Reviews. 1982;9(Suppl B):49-53.
16. McCabe M, Smith FP, Macdonald JS, Woolley PV, Goldberg D, Schein PS. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy. Investigational New Drugs 1988;6(3):243-6.
17. Niiranen A, Mattson K. A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials 1985;8(4):336-40.
18. Orr LE, McKernan JF. Antiemetic effect of delta 9-tetrahydrocannabinol in chemotherapy-associated nausea and emesis as compared to placebo and compazine. Journal of Clinical Pharmacology 1981;21(8-9 Suppl):76S-80S.
19. Pomeroy M, Fennelly JJ, Towers M. Prospective randomized double-blind trial of nabilone versus domperidone in the treatment of cytotoxic-induced emesis. Cancer Chemotherapy and Pharmacology 1986;17(3):285-8.
20. Sallan SE, Zinberg NE, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New England Journal of Medicine 1975; Vol. 293:795-7.
21. Steele N, Gralla RJ, Braun Jr DW, Young CW. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treatment Reports 1980;64(2-3):219-24.
22. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer 1982;50(4):636-45.
23. Wada JK, Bogdon DL, Gunnell JC. Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy. Cancer Treatment Reviews 1982;9(Suppl B):39-44.
24. Aapro MS. Prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Arizona Medicine 1981;38(11):843-5.
25. Allan SG. Mechanisms and management of chemotherapy-induced nausea and vomiting. Blood Reviews 1987;1(1):50-7.
26. Anderson PO, McGuire GG. Delta-9-tetrahydrocannabinol as an antiemetic. American Journal of Hospital Pharmacy 1981;38(5):639-46.
27. Artim R, Dibella N. [Tetrahydrocannabinol plus prochlorperazine for refractory nausea and vomiting]. Proceedings of the 19th annual meeting of the American Society of Clinical Oncology. 1983; Vol. 2:85.
28. Bateman DN, Rawlins MD. Therapeutic potential of cannabinoids. British Medical Journal Clinical Research Ed 1982;284(6324):1211-2.
29. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. Journal of Ethnopharmacology 2006;105(1-2):1-25.
30. Biedrzycki BA. Evolving paradigms in chemotherapy-induced nausea and vomiting and symptom management for the breast cancer patient. ONS Connect 2007;22(8 suppl):9-10.
31. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proceedings of the American Association for Cancer Research 1982;23:514.
32. Carey MP, Burish TG, Brenner DE. Delta-9-tetrahydrocannabinol in cancer chemotherapy: research problems and issues. Annals of Internal Medicine 1983;99(1):106-14.
33. Chan HSL, Correia JA, MacLeod SM. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial. Pediatrics 1987;79(6):946-52.
34. Chang AE, Shiling DJ, Stillman RC. A prospective randomized trial of delta-9-tetrahydrocannabinol (THC) as an antiemetic in patients receiving high dose methotrexate (MTX). American Society of Clinical Oncology 1979:No-C-357.
35. Citron ML Herman TS Vreeland F. Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treatment Reports 1985;69(1):109-12.
36. Cocchetto DM, Cook LF, Cato AE. A critical review of the safety and antiemetic efficacy of delta-9- tetrahydrocannabinol. Drug Intelligence and Clinical Pharmacy 1981;15(11):867-75.
37. Colls BM. Cannabis and cancer chemotherapy. Lancet 1980; Vol. 1:1187-8.
38. Colls BM, Ferry DG, Gray AJ. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. New Zealand Medical Journal 1980;91(662):449-51.
39. Cone LA, Greene DS, Helm NA. Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting. Cancer Treatment Reviews 1982;9(Suppl B):63-70.
40. Costa B. On the pharmacological properties of 9-tetrahydrocannabinol (THC). Chemistry and Biodiversity 2007;4(8):1664-77.
41. Cotter J. Efficacy of crude marijuana and synthetic delta-9-tetrahydrocannabinol as treatment for chemotherapy-induced nausea and vomiting: a systematic literature review. Oncology Nursing Forum 2009; Vol. 36, issue 3:345-52.
42. Cronin CM, Sallan SE, Gelber R, Lucas VS, Laszlo J. Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. Journal of Clinical Pharmacology 1981;21(8-9 Suppl):43S-50S.
43. Croxford JL. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs 2003;17:179-202.
44. Cunningham D, Forrest GJ, Soukop M. Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs. British Medical Journal 1985;291(6499):864-5.
45. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, et al. A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. European Journal of Cancer and Clinical Oncology 1988;24(4):685-9.
46. Dalzell AM, Bartlett H, Lilleyman JS. Nabilone: an alternative antiemetic for cancer chemotherapy. Archives of Disease in Childhood 1986;61(5):502-5.
47. Darmani NA. Cannabinoid-induced hyperemesis: a conundrum-from clinical recognition to basic science mechanisms. Pharmaceuticals 2010;3(7):2163-77.
48. Davis M, Maida V, Daeninck P, Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. Supportive Care in Cancer 2007;15(1):63-71.
49. Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opinion on Investigational Drugs 2008;17(1):85-95.
50. Devine ML, Dow GJ, Greenberg BR, Holstein DW, Icaza L, Jue PY, et al. Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study. Clinical Pharmacy 1987;6(4):319-22.
51. Dodds LJ. The control of cancer chemotherapy-induced nausea and vomiting. Journal of Clinical Hospital Pharmacy 1985;10(2):143-66.
52. Dow GJ, Meyers FH, Stanton W, Devine ML. Serious reactions to oral delta-9-tetrahydrocannabinol in cancer chemotherapy patients. Clinical Pharmacy 1984;3(1):14.
53. Duran M, Perez E, Abanades S, Vidal X, Saura C, Majem M, et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. British Journal of Clinical Pharmacology 2010;70(5):656-63.
54. Ekert H, Waters KD, Jurk IH, Mobilia J, Loughnan P. Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Medical Journal of Australia 1979;2(12):657-9.
55. Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, et al. Antiemesis: clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2007;5(1):12-33.
56. Feyer P, Jordan K. Update and new trends in antiemetic therapy: the continuing need for novel therapies. Annals of Oncology 2011;22(1):30-8.
57. Fiore JJ, Gralla RJ. Pharmacologic treatment of chemotherapy-induced nausea and vomiting. Cancer Investigation 1984;2(5):351-61.
58. Fox FJ, Baker JJ, Lokey JL. Nabilone as an antiemetic. New England Journal of Medicine 1979;301(13):728.
59. Galal AM, Slade D, Gul W, El-Alfy AT, Ferreira D, Elsohly MA. Naturally occurring and related synthetic cannabinoids and their potential therapeutic applications. Recent Patents on CNS Drug Discovery 2009;4(2):112-36.
60. Gallego Fernandez C, Ferrandiz Gosalbez JR. Nausea and vomiting induced by cancer chemotherapy. Review of Cannabis and its antiemetic effects. Farmacia Clinica 1984;1(9):51-62.
61. Gerhartz HH, Binsack T, Hiller E. Levonantradol for the treatment of chemotherapy-induced nausea and vomiting. Klinische Wochenschrift 1983;61(14):719-21.
62. Gerra G, Zaimovic A, Gerra ML, Ciccocioppo R, Cippitelli A, Serpelloni G, et al. Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Patents on CNS Drug Discovery 2010;5(1):46-52.
63. Goodman M. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting. Oncology Nursing Forum 1997;24(7 Suppl):20-32.
64. Gorter RW. Cancer cachexia and cannabinoids. Forschende Komplementarmedizin 1999;6(Suppl 3):21-2.
65. Grunberg SM. Advances in the management of nausea and vomiting induced by non-cisplatin containing chemotherapeutic regimens. Blood Reviews 1989;3(4):216-21.
66. Guzman M. Cannabinoids: potential anticancer agents. Cancer 2003;3(10):745-55.
67. Heim ME, Queisser W, Altenburg HP. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Cancer Chemotherapy and Pharmacology 1984;13(2):123-5.
68. Herrstedt J, Aapro MS, Smyth JF, Del Favero A. Corticosteroids, dopamine antagonists and other drugs. Supportive Care in Cancer 1998;6(3):204-14.
69. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nature Clinical Practice Oncology 2008;5(1):32-43.
70. Higi M, Niederle N, Bremer K, Schmitt G, Schmidt CG, Seeber S. Levonantradol in the treatment of nausea and vomiting caused by cytostatic drugs (author's translation) clinical studies [German]. Deutsche Medizinische Wochenschrift 1982;107(3):1232-4.
71. Hiller E, Gerhartz H. New aspects in the antiemetic therapy of cytostatic drug-induced vomiting [German]. Klinische Wochenschrift 1984;62(10):441-5.
72. Hutcheon AW, Palmer JBD, Soukop M. A randomised multicentre single blind comparison of cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy. European Journal of Cancer and Clinical Oncology 1983;19(8):1087-90.
73. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Critical Reviews in Oncology-Hematology 2007;61(2):162-75.
74. Jordan K, Roila F, Molassiotis A, Maranzano E, Clark-Snow RA, Feyer P, et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009. Supportive Care in Cancer 2011;19(Suppl 1):S37-42.
75. Kearsley JH, Tattersall MH. Recent advances in the prevention or reduction of cytotoxic-induced emesis. Medical Journal of Australia 1985;143(8):341-6.
76. Kenny JB, Wilkinson PM. Levonantradol effectiveness in cancer patients resistant to conventional anti-emetics. Clinical Oncology 1982;8(4):335-9.
77. Kluin-Nelemans JC, Meuwissen Th OJA, Nelemans FA, Maes RAA. Tetrahydrocannabinol as antiemetic in patients treated with cytostatics: double blind crossover trial against placebo. Nederlands Tijdschrift voor Geneeskunde 1981;125(2):900-1.
78. Kluin-Nelemans JC, Meuwissen Th OJA, Nelemans FA, Maes RAA. 9-Tetrahydrocannabinol (THC) as an anti-emetic in patients treated with cancer chemotherapy. A double-blind cross-over trial against placebo. Netherlands Journal of Medicine 1981;24(2):90.
79. Krasnow SH. New directions in managing chemotherapy-related emesis. Oncology 1991;5(9 Suppl):19-24.
80. Kreutz S. The magic plant as an antiemetic. Cannabinoids for treatment of nausea and vomiting [German]. Pharmazie in Unserer Zeit 2007;36(5):389-92.
81. Lane M, Vogel CL, Ferguson J, Krasnow S, Saiers JH, Hamm J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proceedings of the American Society of Clinical Oncology 1989; Vol. 8:326, Abstract 1269.
82. Lane M, Smith FE, Sullivan RA, Plasse TF. Dronabinol and prochlorperazine alone and in combination as antiemetic agents for cancer chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials 1990;13(6):480-4.
83. Laszlo J. Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treatment Reviews 1982;9(Suppl B):3-9.
84. Levitt M, Wilson A, Bowman D, Kemel S, Krepart G, Marks V, et al. Physiologic observations in a controlled clinical trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in cancer chemotherapy. Ophthalmologic implications. Journal of Clinical Pharmacology 1981;21(8-9 Suppl):103S-9S.
85. Levitt M, Faiman C, Hawks R, Wilson A. Randomized double blind comparison of delta-9-tetrahydrocannabinol and marijuana as chemotherapy antiemetics [abstract]. Proceedings - Annual Meeting of American Society of Clinical Oncology 1984; Vol. 3:91, Abstract C-354.
86. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer Journal 2008;14(2):85-93.
87. Long A, Mioduszewski JNR. A randomized double-blind cross-over comparison of the antiemetic activity of levonantradol and prochlorperazine. Proceedings of the American Society of Clinical Oncology 1982;1:C-220.
88. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care 2008;17(5):431-43.
89. Mechoulam R, Carlini EA. Toward drugs derived from cannabis. Naturwissenschaften 1978;65(4):174-9.
90. Mechoulam R. Recent advantages in cannabinoid research. Forschende Komplementarmedizin 1999;6(Suppl 3):16-20.
91. Mechoulam R, Hanus L. The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Research and Management 2001;6(2):67-73.
92. Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang HM, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion 2007;23(3):533-43.
93. Murakami M, Ota K. Recent advances in the management of chemotherapy-induced emesis [Japanese]. Japanese Journal of Cancer Chemotherapy 1986;13(3):401-11.
94. Musty RE, Rossi R. Effects of smoked cannabis and oral DELTA9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: a review of state clinical trials. Journal of Cannabis Therapeutics 2001; Vol. 1, issue 1:29.
95. Nagy CM, Furnas BA, Einhorn LH, Bond WH. Nabilone (N) anti-emetic crossover study in cancer chemotherapy patients. American Association for Cancer Research and American Society of Clinical Oncology 1978;19:30.
96. Navari RM. Pharmacological management of chemotherapy-induced nausea and vomiting. Drugs 2009;69(5):515-33.
97. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opinion on Pharmacotherapy 2009;10(4):629-44.
98. Niederle N, Schutte J, Schmidt CG. Crossover comparison of the antiemetic efficacy of nabilone and alizapride in patients with nonseminomatous testicular cancer receiving cisplatin therapy. Klinische Wochenschrift 1986;64(8):362-5.
99. Niiranen A, Mattson K. Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. American Journal of Clinical Oncology 1987;10(4):325-9.
100. Nyman JV, Fritz WL. A review of the antiemetic use of delta-9-tetrahydrocannabinol and prescribing requirements. Arizona Medicine 1982;39(1):38-43.
101. Orr LE, McKernan JF, Bloome B. Antiemetic effect of tetrahydrocannabinol. Compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Archives of Internal Medicine 1980;140(11):1431-3.
102. Penta JS, Poster DS, Bruno S, Macdonald JS. Clinical trials with antiemetic agents in cancer patients receiving chemotherapy. Journal of Clinical Pharmacology 1981;21(8-9):11S-22S.
103. Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JWR, et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. International Journal of Clinical Pharmacy 2011;33(1):33-43.
104. Phillips RS, Gopaul S, Gibson F, Houghton E, Craig JV, Light K, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD007786.pub2]
105. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacology, Biochemistry and Behavior 1991;40(3):695-700.
106. Porta I, Sales J, Schoenenberger I, Arnaiz JA. Cannabinoids, a myth or a scientific reality?. Medicina Paliativa 2002;9(3):129-33.
107. Poster DS, Penta JS, Bruno S, Macdonald JS. Delta 9-tetrahydrocannabinol in clinical oncology. JAMA 1981;245(20):2047-51.
108. Reynolds R. Comparative efficacy of dronabinol and megestrol acetate. Journal of Clinical Oncology 2002;20(12):2912-3; author reply 2913.
109. Sallan S, Zinberg N, Frei E. Oral delta 9 tetrahydrocannabinol (THC) in the prevention of vomiting (V) associated with cancer chemotherapy (CC). Annual Meeting, proceedings of the American Association for Cancer Research 1975; Vol. 16:575.
110. Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer. A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. New England Journal of Medicine 1980;302(3):135-8.
111. Schuette J, Niederle N, Krischke W. Randomized crossover trial comparing the antiemetic efficacy of nabilone versus alizapride in patients (pts) with nonseminomatous testicular cancer (NSTC) receiving low-dose cisplatin therapy. Proceedings of the American Association for Cancer Research 1985;26:665.
112. Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. Journal of Clinical Pharmacology 1984;24(4):155-9.
113. Slatkin NE. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting: beyond prevention of acute emesis. Journal of Supportive Oncology 2007;5(Suppl 3):1-9.
114. Smith PF. Will medicinal cannabinoids prove to be useful clinically?. Current Drug Therapy 2007;2(2):143-50.
115. Stambaugh JE, McAdams J, Vreeland F. A phase II randomized trial of the antiemetic activity of levonantradol (CP-50, 556) in cancer patients receiving chemotherapy. Proceedings of the American Society of Clinical Oncology 1982;1:C-240.
116. Stambaugh Jr JE, McAdams J, Vreeland F. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. Journal of Clinical Pharmacology 1984;24(11-12):480-5.
117. Steele N, Braun D, O'Hehir M, Young C. Double-blind comparison of the antiemetic effects of nabilone and prochlorperazine on chemotherapy-induced emesis. Cancer Treatment Reports 1979; Vol. 64, issue 2-3:219-24.
118. Stewart DJ. Cancer therapy, vomiting, and antiemetics. Canadian Journal of Physiology & Pharmacology 1990;68(2):304-13.
119. Stuart JFB, Welsh Sangster G, Scullion M, Cash H, Kaye SB, Calman KC. The anti-emetic potential of oral levonantradol in patients receiving cancer chemotherapy. British Journal of Cancer 1982; Vol. 46:492.
120. Stuart-Harris RC, Mooney CA, Smith IE. Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy. Clinical Oncology 1983;9(2):143-6.
121. Sweet DL. Marijuana for drug-induced nausea and vomiting. JAMA 1980;243(12):1265.
122. Toth J, Szanto J. Prophylaxis of chemotherapy-induced vomiting and nausea [Hungarian]. Magyar Onkologia 2008;52(4):391-4.
123. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323(7303):16-21.
124. Ungerleider JT, Sarna G, Fairbanks LA, Goodnight J, Andrysiak T, Jamison K. THC or compazine for the cancer chemotherapy patient - the UCLA study. Part II: patient drug preference. American Journal of Clinical Oncology 1985;8(2):142-7.
125. Venner P, Bruera E, Drebit D, Shankowsky H. Intensive treatment scheduling of nabilone plus dexamethasone (DM) vs metoclopramide plus DM in cisplatin-induced emesis. Proceedings of the American Society of Clinical Oncology 1986;5:253.
126. Vincent BJ, McQuiston DJ, Einhorn LH. Review of cannabinoids and their antiemetic effectiveness. Drugs 1983;25(Suppl 1):52-62.
127. Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Annals of Internal Medicine 1997;126(10):791-8.
128. Wang T, Collet JP, Shapiro S, Ware MA. Adverse effects of medical cannabinoids: a systematic review. Canadian Medical Association Journal 2008;178(13):1669-78.
129. Ward A, Holmes B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1985;30(2):127-44.
130. Ware MA, Daeninck P, Maida V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Therapeutics and Clinical Risk Management 2008;4(1):99-107.
131. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria 2008;30(3):271-80.
132. Citron ML, Herman TS, Fossieck BE, Krasnow SH, Vreeland F, Harwood S, et al. Double-blind, randomised, crossover study of the antiemetic effect of levonantradol versus tetrahydrocannabinol. Proceedings of the American Association of Cancer Research 1983;24:165.
133. Earhart RH, Koeller JM. Levonantradol vs prochlorperazine as parenteral antiemetics in cancer patients receiving cisplatin chemotherapy. Proceedings of the American Association for Cancer Research. 1983;24:163.
134. Jhangiani H, Vredenburgh J, Barbato L, Yang H, Yang H M, Baranowski V, et al. Dronabinol or ondansetron alone and combined for delayed chemotherapy-induced nausea and vomiting (CINV). Abstracts for the 47th Annual Meeting of the American Society of Hematology; 2005 Dec 10-13; Atlanta, Georgia 2005; Vol. 106:477.
135. Neidhart JA, Gagen MM, Wilson HE, Young DC. Comparative trial of the antiemetic effects of THC and haloperidol. Journal of Clinical Pharmacology 1981;21(8-9 Suppl):38S-42S.
136. Barowski MT. Advances in anti-emetic therapy. Cancer Treatment Reviews 1984;11:237-56.
137. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology 2011;29(31):4189-96.
138. Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, et al. Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects. Oncologist 2014;19(2):127-34.
139. Bonnie RJ, Whitebread CH. The Marijuana Conviction: a History of Marijuana Prohibition in the United States. Charlottesville, VA: University Press of Virginia: The Lindesmith Center, 1974.
140. Cohen, J Statistical power analysis for th ebehavioural sciences. Statistical power analysis for the behavioural sciences. 2nd Edition. New Jersey: Lawrence Erlbaum, 1988.
141. Darmani NA. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB (1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001;24:198-203.
142. de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, v Beurden V, Stoter G, et al. Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. British Journal of Cancer 1997;76(8):1055-61.
143. De Mulder PHM. Measurement of success: parameters of efficacy. British Journal of Cancer 1992;66(Suppl XIX):S68.
144. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ, 2001:285-312.
145. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992;258:1946-9.
146. Dubey S, Brown RL, Esmond SL, Bowers BJ, Healy JM, Schiller JH. Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. Journal of Supportive Oncology 2005;3(2):149-54.
147. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. Journal of Clinical Oncology 1999;17(9):2971-94.
148. Gralla RJ, Roila F, Tonato M, Herstedt J. MASCC antiemetic guidelines, 2013. www.mascc.org/antiemetic-guidelines (accessed 29 October 2015).
149. Grotenhermen F. Effects of cannabis and the cannabinoids. In: Grotenhermen F, Russo E editor(s). Pharmacology, Toxicology and Therapeutic Potential. 1st Edition. New York: The Haworth Press, Inc., 2002:55-65.
150. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
151. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
152. Huang JQ, Zheng GF, Chan GC, Karlberg J, Lam SK, Wong BC. Efficacy of current antiemetic treatments for preventing delayed chemotherapy-induced nausea and vomiting: a meta-analysis of randomized controlled trials. Clinical Research and Regulatory Affairs 2004;21(3-4):191-212.
153. Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. Journal of Clinical Oncology 2000;18:3409-22.
154. Janelsins MC, Tejani MA, Kamen C, Peoples AR, Mustian KM, Morrow GR. Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opinion on Pharmacotherapy 2013;14(6):757-66.
155. Karniol IG. Cannabis sativa and derivatives. In: Seibel SD, Toscano JRA editor(s). Dependência de Drogas. 1st Edition. Rio de Janeiro: Atheneu, 2001:131-42.
156. Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, et al. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Breast Cancer Research and Treatment 2013;142(1):107.
157. Machado Rocha FC, Stefano SC, De Cássia Haiek R, Rosa Oliveira LMQ, da Silveira DX. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. European Journal of Cancer Care 2008;17(5):431-43.
158. Martin M. Myths and realities of antiemetic treatment. British Journal of Cancer 1992;66(Suppl XIX):S46-51.
159. Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Annals of Oncology 1998;9(8):811-9.
160. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology 1995;50:83-90.
161. National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines) Antiemesis Version 2, 2014. www.nccn.org/professionals/physician_gls/f_guidelines.asp, last retrieved 09.11.15.
162. National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Antiemesis Version 2. http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf, last retrieved 09.11.15.
163. Olver IN. Methodology in anti-emetic trials. Oncology 1992;49:269-72.
164. Olver IN. Antiemetic study design: desirable objectives, stratifications and analyses. British Journal of Cancer 1992;66(Suppl XIX):S30-4.
165. Olver I. Two decades of progress in treating chemotherapy induced emesis. Cancer Forum 2004;28:140-3.
166. Pater JL, Willan AR. Methodologic issues in trials of antiemetics. Journal of Clinical Oncology 1984;2(5):484-7.
167. Rhodes VA, Watson PM, Johnson MH. Development of reliable and valid measures of nausea and vomiting. Cancer Nursing 1984;7(1):33-41.
168. Rodríguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, Bilbao A, Cippitelli A, Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol and Alcoholism 2005;40(1):2-14.
169. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Annals of Oncology 2010;21(5):232-43.
170. Russo S, Cinausero M, Gerratana L, Bozza C, Iacono D, Driol P, et al. Factors affecting patient's perception of anticancer treatments side-effects: an observational study. Expert Opinion on Drug Safety 2014;13(2):139-50.
171. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspective. Journal of Support Oncology 2007;5:5-12.
172. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications 1995;215:89-97.
173. Sun CC, Bodurka DC, Donato ML, Rubenstein EB, Borden CL, Basen-Engquist K, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. Gynecologic Oncology 2002;87(1):118-28.
174. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Supportive Care in Cancer 2003;11:137-43.
175. Wilcox PM, Fetting JH, Nettesheim KM, Abeloff MD. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. Cancer Treatment Reports 1982;66:1601-4.